Sweeping recalls of a class of high blood pressure drugs known as ARBs, or angiotensin II receptor blockers, has resulted in a shortage, Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb and FDA director of drug evaluation and research Dr. Janet Woodcock said in a joint statement. And the problem will probably get worse. The shortage is among ARBs that contain the active drug ingredient valsartan, and may soon also affect other ARBs that contain losartan and irbesartan. The shortage is due to recalls of the drug over an unexpected impurity, which was identified as a chemical called NDMA ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.